High-Throughput Enabled Iridium-Catalyzed C–H Borylation Platform for Late-Stage Functionalization
In this work, we present a dedicated, high-throughput reaction optimization platform allowing for the rapid evaluation of regiodivergent C-H borylation protocols while minimizing the amount of starting material required. The workflow was applied to a diverse set of fragment-like compounds, pharmaceuticals, and agrochemicals, and its practicality was demonstrated by successfully isolating 36 derivatives of bioactive compounds. Leveraging the informer library approach, we provide a comprehensive, side-by-side comparison of catalytic methods, revealing insights into the strengths, limitations, and versatility of each borylation protocol. Surprising reactivity patterns, effectiveness of ligand-free C-H borylation, and the utility of previously reported directed C-H borylation catalysts outside of their expected substrate scope have been noticed. This study highlights the potential of dedicated high-throughput optimization platforms to expand the practical utility of late-stage functionalization protocols for pharmaceutical and agrochemical research.
Authors
- Magnus J. Johansson (ORCID: https://orcid.org/0000-0002-0904-2835)
- Janis M. Zakis (ORCID: https://orcid.org/0000-0003-0882-2124)
- Tomáš Šmejkal (ORCID: https://orcid.org/0000-0001-9458-0963)
- Joanna Wencel‐Delord (ORCID: https://orcid.org/0000-0002-7094-5443)
- Rebeka Anna Līpiņa
- Simon R. Williams
- Sharon Bell
- Maurus Mathis
Institutions
- University of Würzburg (DE)
- AstraZeneca (Sweden) (SE)
- Syngenta (Switzerland) (CH)
Publication Details
- Journal
- ACS Catalysis
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1021/acscatal.4c07711
- Citations
- 5
- Primary Topic
- Catalytic C–H Functionalization Methods
- Type
- article
- Field-Weighted Citation Impact
- 4.68
Funders
- AstraZeneca
- European Commission
- Horizon 2020 Framework Programme
- H2020 Marie Skłodowska-Curie Actions